New drug combo shows promise for rare kidney cancer
NCT ID NCT05220267
First seen Jul 07, 2026 · Last updated Jul 08, 2026 · Updated 1 time
Summary
This trial tests a combination of two drugs—anlotinib (a pill that blocks blood vessel growth to tumors) and sintilimab (an IV immunotherapy that helps the immune system attack cancer cells)—as a first treatment for people with advanced non-clear cell renal cell carcinoma, a rare and aggressive kidney cancer. The study includes about 44 adults with various subtypes of this cancer. Researchers are measuring how long the cancer stays under control and how many patients respond to the treatment.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- Anlotinib plus Sintilimab
- What this could lead to
- If successful, this combination could offer a new first-line treatment option for people with a rare and hard-to-treat form of kidney cancer.
- What could go wrong
- This is a small, early-phase trial (Phase 2) with only 44 participants, so results may not apply broadly. The drug combination can cause side effects like fatigue, high blood pressure, or immune-related reactions.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for NON CLEAR CELL RENAL CARCINOMA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Cancer Center, Sun Yat-sen University
Guangzhou, Guangdong, 510060, China